Inspire Medical Systems Revises 2026 Revenue Guidance Downward Due to Reimbursement Uncertainty
summarizeSummary
Inspire Medical Systems reported strong Q4 and full-year 2025 financial results but revised its 2026 revenue guidance downward, citing uncertainty around CPT coding and physician reimbursement for its Inspire V system.
check_boxKey Events
-
Strong Q4 & FY25 Financial Performance
Revenue increased 12% in Q4 to $269.1 million and 14% for full-year 2025 to $912.0 million, with improved gross margins and operating cash flow. Net income per diluted share was $4.66 for Q4 and $4.89 for FY25.
-
Revised 2026 Revenue Guidance
The company lowered its full-year 2026 revenue outlook to a range of $950 million to $1.0 billion, representing 4% to 10% annual growth. This is a revision from previously announced positive guidance.
-
Reimbursement Uncertainty Impacts Outlook
The revised guidance is attributed to coding uncertainty and the estimated impact of transitioning to CPT code 64582 with a -52 modifier for the Inspire V procedure, which could affect physician reimbursement rates.
-
Board Declassification Proposal
The Board approved a proposal to declassify the Board of Directors, moving towards annual director elections and removing the 'for cause' removal provision, subject to shareholder approval at the 2026 Annual Meeting.
auto_awesomeAnalysis
The primary market-moving aspect of this filing is the downward revision of Inspire Medical Systems' 2026 revenue guidance. While the company delivered strong financial results for Q4 and full-year 2025, the updated outlook reflects significant uncertainty regarding reimbursement for its new Inspire V system due to CPT coding changes. This potential impact on physician fees and usage could hinder future growth, especially as the stock is trading near its 52-week low. Investors will closely monitor the company's efforts to secure a long-term CPT code solution and minimize the financial impact on physicians. The proposed corporate governance changes, while positive for shareholder rights, are secondary to the immediate financial outlook concerns.
At the time of this filing, INSP was trading at $61.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $2B. The 52-week trading range was $64.46 to $197.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.